Skip to main content
Erschienen in: Inflammation 4/2009

01.08.2009

Aspirin Inhibits MMP-2 and MMP-9 Expression and Activity Through PPARα/γ and TIMP-1-Mediated Mechanisms in Cultured Mouse Celiac Macrophages

verfasst von: Yao Yiqin, Xie Meilin, Xue Jie, Zhang Keping

Erschienen in: Inflammation | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Aspirin is an anti-inflammatory drug, and has been widely used for the prevention of cardio-cerebrovascular events. Matrix metalloproteinase (MMP)-2 and MMP-9 can degrade the extracellular matrix and may be critical for the development and disruption of atherosclerotic plaques, while tissue inhibitor of metalloproteinase (TIMP)-1 may inhibit the degradation of extracellular matrix. The purpose of present study was to investigate the inhibitory effects of aspirin on MMP-2 and MMP-9 expression and activity in cultured mouse celiac macrophages, and to determine the possible mechanisms. The results showed that MMP-2/9 mRNA expression and release were significantly decreased after cultured mouse celiac macrophages were treated with aspirin 12.5–50 μg/ml for 24 h, while the TIMP-1 mRNA expression and release, and peroxisome proliferator-activated receptor (PPAR) α/γ mRNA expression were increased after the same treatment. Moreover the aspirin-induced down-regulation of MMP-2/9 mRNA expression and reduction of MMP-9 release were notably alleviated after pretreatment with specific inhibitors of PPARα/γ. These results suggested that aspirin could inhibit the expression and release of MMP-2/9 by up-regulation of PPARα/γ gene expression, and also inhibit the activity of MMP-2/9 by induction of TIMP-1 expression, which might be good for the stabilization of atherosclerotic plaques and the prevention of cardio-cerebrovascular events.
Literatur
2.
Zurück zum Zitat Shah, P. K. 1998. Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc. Med. 3:199–206.PubMed Shah, P. K. 1998. Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc. Med. 3:199–206.PubMed
3.
Zurück zum Zitat Dollery, C. M., J. R. McEwan, and A. M. Henney. 1995. Matrix metalloproteinases and cardiovascular disease. Circ. Res. 77:863–868.PubMed Dollery, C. M., J. R. McEwan, and A. M. Henney. 1995. Matrix metalloproteinases and cardiovascular disease. Circ. Res. 77:863–868.PubMed
4.
Zurück zum Zitat Galis, Z. S., and J. J. Khatri. 2002. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 90:251–262.PubMed Galis, Z. S., and J. J. Khatri. 2002. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 90:251–262.PubMed
5.
7.
Zurück zum Zitat Ezzahiri, R., F. R. Stassen, H. A. Kurvers, M. M. van Pul, P. J. Kitslaar, and C. A. Bruggeman. 2003. Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice. Eur. J. Vasc. Endovasc. Surg. 26:88–95. doi:10.1053/ejvs.2002.1913.PubMedCrossRef Ezzahiri, R., F. R. Stassen, H. A. Kurvers, M. M. van Pul, P. J. Kitslaar, and C. A. Bruggeman. 2003. Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice. Eur. J. Vasc. Endovasc. Surg. 26:88–95. doi:10.​1053/​ejvs.​2002.​1913.PubMedCrossRef
8.
Zurück zum Zitat Nishimura, K., M. Ikebuchi, Y. Kanaoka, S. Ohgi, E. Ueta, E. Nanba, and H. Ito. 2003. Relationships between matrix metalloproteinases and tissue inhibitor of metalloproteinases in the wall of abdominal aortic aneurysms. Int. Angiol. 22:229–238.PubMed Nishimura, K., M. Ikebuchi, Y. Kanaoka, S. Ohgi, E. Ueta, E. Nanba, and H. Ito. 2003. Relationships between matrix metalloproteinases and tissue inhibitor of metalloproteinases in the wall of abdominal aortic aneurysms. Int. Angiol. 22:229–238.PubMed
9.
Zurück zum Zitat Auge, N., F. Maupas-Schwalm, M. Elbaz, J. C. Thiers, A. Waysbort, S. Itohara, H. W. Krell, R. Salvayre, and A. Negre-Salvayre. 2004. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. Circulation. 110:571–578. doi:10.1161/01.CIR.0000136995.83451.1D.PubMedCrossRef Auge, N., F. Maupas-Schwalm, M. Elbaz, J. C. Thiers, A. Waysbort, S. Itohara, H. W. Krell, R. Salvayre, and A. Negre-Salvayre. 2004. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. Circulation. 110:571–578. doi:10.​1161/​01.​CIR.​0000136995.​83451.​1D.PubMedCrossRef
10.
Zurück zum Zitat Zaltsman, A. B., S. J. George, and A. C. Newby. 1999. Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity. Arterioscler. Thromb. Vasc. Biol. 19:1700–1707.PubMed Zaltsman, A. B., S. J. George, and A. C. Newby. 1999. Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity. Arterioscler. Thromb. Vasc. Biol. 19:1700–1707.PubMed
11.
Zurück zum Zitat Vincenti, M. P. 2001. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol. Biol. 151:121–148.PubMed Vincenti, M. P. 2001. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol. Biol. 151:121–148.PubMed
12.
Zurück zum Zitat Blanquart, C., O. Barbier, J. C. Fruchart, B. Staels, and C. Glineur. 2003. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J. Steroid Biochem. Mol. Biol. 85:267–273. doi:10.1016/S0960-0760(03)00214-0.PubMedCrossRef Blanquart, C., O. Barbier, J. C. Fruchart, B. Staels, and C. Glineur. 2003. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J. Steroid Biochem. Mol. Biol. 85:267–273. doi:10.​1016/​S0960-0760(03)00214-0.PubMedCrossRef
14.
Zurück zum Zitat Ringseis, R., N. Schulz, D. Saal, and K. Eder. 2008. Troglitazone but not conjugated linoleic acid reduces gene expression and activity of matrix-metalloproteinases-2 and -9 in PMA-differentiated THP-1 macrophages. J. Nutr. Biochem. 19:594–603. doi:10.1016/j.jnutbio.2007.08.003.PubMedCrossRef Ringseis, R., N. Schulz, D. Saal, and K. Eder. 2008. Troglitazone but not conjugated linoleic acid reduces gene expression and activity of matrix-metalloproteinases-2 and -9 in PMA-differentiated THP-1 macrophages. J. Nutr. Biochem. 19:594–603. doi:10.​1016/​j.​jnutbio.​2007.​08.​003.PubMedCrossRef
15.
Zurück zum Zitat Hanefeld, M., N. Marx, A. Pfutzner, W. Baurecht, G. Lubben, E. Karagiannis, U. Stier, and T. Forst. 2007. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the piostat study. J. Am. Coll. Cardiol. 49:290–297. doi:10.1016/j.jacc.2006.08.054.PubMedCrossRef Hanefeld, M., N. Marx, A. Pfutzner, W. Baurecht, G. Lubben, E. Karagiannis, U. Stier, and T. Forst. 2007. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the piostat study. J. Am. Coll. Cardiol. 49:290–297. doi:10.​1016/​j.​jacc.​2006.​08.​054.PubMedCrossRef
16.
Zurück zum Zitat Marfella, R., M. D’Amico, C. D. Filippo, A. Baldi, M. Siniscalchi, F. C. Sasso, M. Portoghese, O. Carbonara, B. Crescenzi, P. Sangiuolo, G. F. Nicoletti, R. Rossiello, F. Ferraraccio, F. Cacciapuoti, M. Verza, L. Coppola, F. Rossi, and G. Paolisso. 2006. Increased activity of the ubiquitin–proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque effects of rosiglitazone treatment. J. Am. Coll. Cardiol. 47:2444–2455. doi:10.1016/j.jacc.2006.01.073.PubMedCrossRef Marfella, R., M. D’Amico, C. D. Filippo, A. Baldi, M. Siniscalchi, F. C. Sasso, M. Portoghese, O. Carbonara, B. Crescenzi, P. Sangiuolo, G. F. Nicoletti, R. Rossiello, F. Ferraraccio, F. Cacciapuoti, M. Verza, L. Coppola, F. Rossi, and G. Paolisso. 2006. Increased activity of the ubiquitin–proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque effects of rosiglitazone treatment. J. Am. Coll. Cardiol. 47:2444–2455. doi:10.​1016/​j.​jacc.​2006.​01.​073.PubMedCrossRef
18.
Zurück zum Zitat Akaike, M., H. Azuma, A. Kagawa, K. Matsumoto, I. Hayashi, K. Tamura, T. Nishiuchi, T. Iuchi, N. Takamori, K. Aihara, T. Yoshida, Y. Kanagawa, and T. Matsumoto. 2002. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin. Chem. 48:1454–1459.PubMed Akaike, M., H. Azuma, A. Kagawa, K. Matsumoto, I. Hayashi, K. Tamura, T. Nishiuchi, T. Iuchi, N. Takamori, K. Aihara, T. Yoshida, Y. Kanagawa, and T. Matsumoto. 2002. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin. Chem. 48:1454–1459.PubMed
21.
22.
Zurück zum Zitat Murono, S., T. Yoshizaki, H. Sato, H. Takeshita, M. Furukawa, and J. S. Pagano. 2000. Aspirin inhibits tumor cell invasiveness induced by Epstein–Barr virus latent membrane protein-1 through suppression of matrix metalloproteinase-9 expression. Cancer Res. 60:2555–2561.PubMed Murono, S., T. Yoshizaki, H. Sato, H. Takeshita, M. Furukawa, and J. S. Pagano. 2000. Aspirin inhibits tumor cell invasiveness induced by Epstein–Barr virus latent membrane protein-1 through suppression of matrix metalloproteinase-9 expression. Cancer Res. 60:2555–2561.PubMed
23.
Zurück zum Zitat Jiang, M. C., C. F. Liao, and P. H. Lee. 2001. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem. Biophys. Res. Commun. 282:671–677. doi:10.1006/bbrc.2001.4637.PubMedCrossRef Jiang, M. C., C. F. Liao, and P. H. Lee. 2001. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem. Biophys. Res. Commun. 282:671–677. doi:10.​1006/​bbrc.​2001.​4637.PubMedCrossRef
24.
Zurück zum Zitat Xue, J., Y. N. Hua, Z. L. Gu, K. Y. Wu, and M. L. Xie. 2008. Study of aspirin on inhibiting the atherosclerotic plaque rupture and MMP-2 expression of abdominal aorta in atherosclerotic rabbits. Chin. Pharmacol. Bull. 24(10):1335–1339. Xue, J., Y. N. Hua, Z. L. Gu, K. Y. Wu, and M. L. Xie. 2008. Study of aspirin on inhibiting the atherosclerotic plaque rupture and MMP-2 expression of abdominal aorta in atherosclerotic rabbits. Chin. Pharmacol. Bull. 24(10):1335–1339.
25.
Zurück zum Zitat Hua, Y. N., J. Xue, F. Sun, L. J. Zhu, and M. L. Xie. 2008. Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPAR α/γ and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Pharmacology 83:18–25. doi:10.1159/000166183.PubMedCrossRef Hua, Y. N., J. Xue, F. Sun, L. J. Zhu, and M. L. Xie. 2008. Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPAR α/γ and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Pharmacology 83:18–25. doi:10.​1159/​000166183.PubMedCrossRef
26.
Zurück zum Zitat Saiki, I., and I. J. Fidler. 1985. Synergistic activation by recombinant mouse IFN-gmma and muramyl dipeptide of tumoricidal properties in mouse macrophages. J. Immunol. 135:684–688.PubMed Saiki, I., and I. J. Fidler. 1985. Synergistic activation by recombinant mouse IFN-gmma and muramyl dipeptide of tumoricidal properties in mouse macrophages. J. Immunol. 135:684–688.PubMed
27.
Zurück zum Zitat Pillinger, M. H., P. B. Rosenthal, S. N. Tolani, B. Apsel, V. Dinsell, J. Greenberg, E. S. L. Chan, P. F. Gomez, and S. B. Abramson. 2003. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J. Immunol. 171:6080–6089.PubMed Pillinger, M. H., P. B. Rosenthal, S. N. Tolani, B. Apsel, V. Dinsell, J. Greenberg, E. S. L. Chan, P. F. Gomez, and S. B. Abramson. 2003. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J. Immunol. 171:6080–6089.PubMed
28.
Zurück zum Zitat Orbe, J., L. Fernandez, J. A. Rodriguez, G. Rabago, M. Belzunce, A. Monasterio, C. Roncal, and J. A. Paramo. 2003. Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis 170:269–276. doi:10.1016/S0021-9150(03)00251-X.PubMedCrossRef Orbe, J., L. Fernandez, J. A. Rodriguez, G. Rabago, M. Belzunce, A. Monasterio, C. Roncal, and J. A. Paramo. 2003. Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis 170:269–276. doi:10.​1016/​S0021-9150(03)00251-X.PubMedCrossRef
29.
Zurück zum Zitat Rouis, M., C. Adamy, N. Duverger, P. Lesnik, P. Horellou, M. Moreau, F. Emmanuel, J. M. Caillaud, P. M. Laplaud, C. Dachet, and M. J. Chapman. 1999. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 100:533–540.PubMed Rouis, M., C. Adamy, N. Duverger, P. Lesnik, P. Horellou, M. Moreau, F. Emmanuel, J. M. Caillaud, P. M. Laplaud, C. Dachet, and M. J. Chapman. 1999. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 100:533–540.PubMed
30.
Zurück zum Zitat Allaire, E., R. Forgough, M. Clowes, B. Starcher, and A. W. Clowes. 1998. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J. Clin. Invest. 102:1413–1420. doi:10.1172/JCI2909.PubMedCrossRef Allaire, E., R. Forgough, M. Clowes, B. Starcher, and A. W. Clowes. 1998. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J. Clin. Invest. 102:1413–1420. doi:10.​1172/​JCI2909.PubMedCrossRef
Metadaten
Titel
Aspirin Inhibits MMP-2 and MMP-9 Expression and Activity Through PPARα/γ and TIMP-1-Mediated Mechanisms in Cultured Mouse Celiac Macrophages
verfasst von
Yao Yiqin
Xie Meilin
Xue Jie
Zhang Keping
Publikationsdatum
01.08.2009
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 4/2009
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-009-9125-3

Weitere Artikel der Ausgabe 4/2009

Inflammation 4/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

22.05.2024 Obstipation Nachrichten

Bei chronischer Verstopfung wirken Kiwis offenbar besser als Flohsamenschalen. Das zeigen die Daten aus einer randomisierten Studie, die der Gastroenterologe Oliver Pech beim Praxis-Update vorstellte.

So häufig greift rheumatoide Arthritis auf Organe über

21.05.2024 Rheumatoide Arthritis Nachrichten

Im Verlauf von rheumatoider Arthritis entwickeln viele Patienten extraartikuläre Manifestationen. Schwedische Forscher haben sich mit der Inzidenz und den Risikofaktoren befasst.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.